# KCNIP4

## Overview
KCNIP4 is a gene that encodes the potassium voltage-gated channel interacting protein 4, a member of the Kv channel-interacting proteins (KChIPs) family. This protein plays a critical role in modulating the activity of voltage-gated potassium channels, particularly those of the Kv4 subfamily, which are essential for the A-type potassium current (I_A) in neurons. The protein is characterized by EF-hand motifs that enable calcium binding, suggesting its function as a calcium sensor in neuronal signaling. Predominantly expressed in the brain, KCNIP4 influences neuronal excitability, synaptic plasticity, and neuroprotection by regulating the inactivation and surface expression of Kv4 channels. Its interactions and regulatory mechanisms are significant in various physiological and pathological contexts, including neuroprotection against excitotoxicity and implications in neurodegenerative diseases, schizophrenia, and certain cancers (Su2019Down‐regulation; Morohashi2002Molecular; Weißflog2013KCNIP4).

## Function
KCNIP4 encodes a protein that is part of the Kv channel-interacting proteins (KChIPs) family, which modulate the activity of voltage-gated potassium channels, particularly the Kv4 subfamily. These channels are responsible for the A-type potassium current (I_A), which is crucial for regulating neuronal excitability and action potential dynamics in neurons (Su2019Down‐regulation; Morohashi2002Molecular). KCNIP4 interacts with the N-terminus of Kv4 channel alpha subunits, affecting their biophysical properties and stabilizing channel complexes, which is essential for proper channel function (Su2019Down‐regulation).

The protein contains EF-hand motifs that bind calcium, suggesting a role as a calcium sensor in modulating channel activity (Morohashi2002Molecular). KCNIP4 is predominantly expressed in the brain, where it influences neuronal signaling and synaptic plasticity by modulating the inactivation and surface expression of Kv4 channels (Weißflog2013KCNIP4). This modulation of potassium currents is vital for maintaining neuronal health and function, particularly in response to synaptic inputs and during repetitive firing (Su2019Down‐regulation). The protein's activity in the brain is linked to its role in protecting neurons from excitotoxicity, highlighting its importance in neuroprotection (Su2019Down‐regulation).

## Clinical Significance
KCNIP4 has been implicated in several clinical conditions due to its role in neuronal function and its interactions with other proteins. In schizophrenia patients, genetic variations in KCNIP4 have been associated with adverse drug reactions to aripiprazole, particularly movement-related side effects such as akathisia. This is attributed to its role in synaptic function and its interaction with KCNA1, which is linked to epileptic ataxia and dyskinesia (Wang2023Genomewide).

In the context of neurodegenerative conditions, KCNIP4 expression is regulated by miR-3068-3p, which plays a protective role against glutamate-induced excitotoxicity. Alterations in KCNIP4 expression can influence neuronal survival, suggesting potential therapeutic targets for conditions like ischemic stroke (Su2019Down‐regulation).

KCNIP4 is also involved in cancer-related processes. It has been disrupted by genetic mutations in renal cell cancer and squamous cell lung cancer, indicating its potential role in cancer progression through calcium ion binding and regulation of RAD21 activity (Schierding2022Genetic).

In cystic fibrosis, SNPs in KCNIP4 have been linked to pancreatic insufficiency, highlighting its role in inflammatory response and potential as a marker for pancreatic status in these patients (Marson2018Pancreatic).

## Interactions
KCNIP4, a member of the potassium channel interacting protein (KChIP) family, is known for its role in modulating the activity of voltage-gated potassium channels, particularly the Kv4 subfamily. KCNIP4 interacts with the N-terminus of Kv4 channel alpha subunits, which is crucial for regulating the A-type potassium current (I_A) and modulating neuronal excitability (Su2019Down‐regulation). This interaction is essential for stabilizing channel complexes and enhancing the surface expression and gating properties of Kv4 channels (Su2019Down‐regulation).

KCNIP4 is also regulated by microRNA miR-3068-3p, which binds to the 3'UTR of KCNIP4, suppressing its expression. Inhibition of miR-3068-3p leads to increased KCNIP4 expression, which enhances I_A and provides neuroprotection against glutamate-induced excitotoxicity (Su2019Down‐regulation). The study by Su et al. highlights that KCNIP4 over-expression can rescue neuronal injury, suggesting its protective role in neurons (Su2019Down‐regulation).

While the context does not provide specific details on physical interactions of KCNIP4 with other proteins or nucleic acids beyond its regulation by miR-3068-3p, it is implied that KCNIP4's interaction with Kv4 channels is a key aspect of its function in neuronal protection (Su2019Down‐regulation).


## References


[1. (Morohashi2002Molecular) Yuichi Morohashi, Noriyuki Hatano, Susumu Ohya, Rie Takikawa, Tomonari Watabiki, Nobumasa Takasugi, Yuji Imaizumi, Taisuke Tomita, and Takeshi Iwatsubo. Molecular cloning and characterization of calp/kchip4, a novel ef-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit kv4. Journal of Biological Chemistry, 277(17):14965–14975, April 2002. URL: http://dx.doi.org/10.1074/jbc.m200897200, doi:10.1074/jbc.m200897200. This article has 131 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m200897200)

[2. (Marson2018Pancreatic) Fernando Augusto Lima Marson, Carmen Sílvia Bertuzzo, Tânia Kawasaki de Araujo, Taís Daiene Russo Hortencio, Antônio Fernando Ribeiro, and José Dirceu Ribeiro. Pancreatic insufficiency in cystic fibrosis: influence of inflammatory response genes. Pancreas, 47(1):99–109, January 2018. URL: http://dx.doi.org/10.1097/mpa.0000000000000963, doi:10.1097/mpa.0000000000000963. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/mpa.0000000000000963)

[3. (Su2019Down‐regulation) Zi‐Jun Su, Xu‐Yi Wang, Chen Zhou, and Zhen Chai. Down‐regulation of mir‐3068‐3p enhances kcnip4‐regulated a‐type potassium current to protect against glutamate‐induced excitotoxicity. Journal of Neurochemistry, 153(5):617–630, December 2019. URL: http://dx.doi.org/10.1111/jnc.14932, doi:10.1111/jnc.14932. This article has 1 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/jnc.14932)

[4. (Schierding2022Genetic) William Schierding, Julia A. Horsfield, and Justin O’Sullivan. Genetic variation as a long-distance modulator of rad21 expression in humans. Scientific Reports, July 2022. URL: http://dx.doi.org/10.1038/s41598-022-15081-1, doi:10.1038/s41598-022-15081-1. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-022-15081-1)

[5. (Wang2023Genomewide) Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, and Weihua Yue. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia, July 2023. URL: http://dx.doi.org/10.1038/s41537-023-00369-6, doi:10.1038/s41537-023-00369-6. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41537-023-00369-6)

[6. (Weißflog2013KCNIP4) Lena Weißflog, Claus-Jürgen Scholz, Christian P. Jacob, Thuy Trang Nguyen, Karin Zamzow, Silke Groß-Lesch, Tobias J. Renner, Marcel Romanos, Dan Rujescu, Susanne Walitza, Susanne Kneitz, Klaus-Peter Lesch, and Andreas Reif. Kcnip4 as a candidate gene for personality disorders and adult adhd. European Neuropsychopharmacology, 23(6):436–447, June 2013. URL: http://dx.doi.org/10.1016/j.euroneuro.2012.07.017, doi:10.1016/j.euroneuro.2012.07.017. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.euroneuro.2012.07.017)